Agenus Inc. Gross Margin

Gross Margin of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending June 29, 2020 was 97.65% (a -2.35% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin decreased by -2.35%
  • Annual Gross Margin for 2019 was 100.0% (a 0.0% decrease from previous year)
  • Annual Gross Margin for 2018 was 100.0% (a 0.0% decrease from previous year)
  • Annual Gross Margin for 2017 was 100.0% (a 0.0% decrease from previous year)
  • Twelve month Gross Margin ending June 29, 2020 was 99.34% (a -0.66% decrease compared to previous quarter)
  • Twelve month trailing Gross Margin decreased by -0.66% year-over-year
Trailing Gross Margin for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
99.34% 100.0% 100.0% 100.0%
Visit stockrow.com/AGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of Agenus Inc.

Most recent Gross Marginof AGEN including historical data for past 10 years.

Interactive Chart of Gross Margin of Agenus Inc.

Agenus Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 97.65% 100.0%
2019 100.0% 100.0% 100.0% 100.0% 100.0%
2018 100.0% 100.0% 100.0% 100.0% 100.0%
2017 100.0% 100.0% 100.0% 100.0% 100.0%
2016 100.0% 100.0% 100.0% 100.0% 100.0%
2015 100.0% 100.0% 100.0% 100.0% 100.0%
2014 100.0% 100.0% 100.0% 100.0% 100.0%
2013 98.32% 89.12% 78.11% 75.41% 82.4%
2012 72.24% 75.0% 79.5% 99.82% 95.79%
2011 100.0% 100.0% 100.0% 100.0% 100.0%
2010 100.0% 89.59% 92.81% 100.0% 96.34%
2009 100.0% 100.0% 100.0%

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Further, it develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bifunctional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. Additionally, the company engages in the development INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390 – an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.